To view the Online Exhibitor Showcase please click here.
BioVectra DCL, located in Prince Edward Island, Canada, is a cGMP manufacturer of Active Pharmaceutical Ingredients, Advanced Intermediates, specialty biochemicals, enzymes, and biomolecules. BioVectra has three, U.S. FDA-inspected manufacturing facilities (June, 2005) which are equipped to provide a range of contract services, which include pre-clinical to Phase III clinical supply, commercial-scale capabilities, and cGMP natural product isolation, extraction, and purification from both plant and animal biomass sources. BioVectra currently has 7 customer specific DMF's registered with the FDA, and areas of technical expertise include: -cGMP manufacturing from development to commercial scale -Plant & Animal-based bioactive extraction -Purification of API's from complex biological matrices -Specialty, bioprocessing reagents - Fermentation (including cytotoxics handling) -cGMP Bioconjugations and MPEG reagent production. BioVectra continues to grow and expand its technology platforms to add value for its partners in pharmaceutical development.
CLICK HERE TO LAUNCH BIOVECTRA PRESENTATIONBioVectra Specialized Capabilities Update: Bridging Project Requirements from Biotech to Classic Pharma
